- Home
- TRC vs CTMX Comparison
TRC vs CTMX Comparison
Compare TRC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- CTMX
- Stock Information
- Founded
- TRC 1843
- CTMX 2008
- Country
- TRC United States
- CTMX United States
- Employees
- TRC N/A
- CTMX N/A
- Industry
- TRC Real Estate
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- CTMX Health Care
- Exchange
- TRC Nasdaq
- CTMX Nasdaq
- Market Cap
- TRC 463.5M
- CTMX 444.3M
- IPO Year
- TRC N/A
- CTMX 2015
- Fundamental
- Price
- TRC $16.55
- CTMX $2.33
- Analyst Decision
- TRC
- CTMX Strong Buy
- Analyst Count
- TRC 0
- CTMX 2
- Target Price
- TRC N/A
- CTMX $5.00
- AVG Volume (30 Days)
- TRC 104.4K
- CTMX 3.3M
- Earning Date
- TRC 08-05-2025
- CTMX 08-07-2025
- Dividend Yield
- TRC N/A
- CTMX N/A
- EPS Growth
- TRC 298.28
- CTMX 128.27
- EPS
- TRC 0.08
- CTMX 0.49
- Revenue
- TRC $42,689,000.00
- CTMX $147,557,000.00
- Revenue This Year
- TRC $0.64
- CTMX N/A
- Revenue Next Year
- TRC N/A
- CTMX N/A
- P/E Ratio
- TRC $207.56
- CTMX $4.78
- Revenue Growth
- TRC 7.04
- CTMX 23.81
- 52 Week Low
- TRC $14.71
- CTMX $0.40
- 52 Week High
- TRC $19.82
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- TRC 53.63
- CTMX 49.57
- Support Level
- TRC $16.06
- CTMX $2.08
- Resistance Level
- TRC $16.55
- CTMX $3.10
- Average True Range (ATR)
- TRC 0.36
- CTMX 0.26
- MACD
- TRC 0.04
- CTMX -0.11
- Stochastic Oscillator
- TRC 77.12
- CTMX 15.20
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.